A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- 11 Mar 2018 Planned number of patients changed from 446 to 544.
- 11 Sep 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 11 Sep 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.